Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

90 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Management of Inoperable Malignant Neoplasms.
Kiess AP, Quon H. Kiess AP, et al. Adv Otorhinolaryngol. 2016;78:157-67. doi: 10.1159/000442136. Epub 2016 Apr 12. Adv Otorhinolaryngol. 2016. PMID: 27093559 Review.
Guiding principles on the education and practice of theranostics.
Pascual TNB, Paez D, Iagaru A, Gnanasegaran G, Lee ST, Sathekge M, Buatti JM, Giammarile F, Al-Ibraheem A, Pardo MA, Baum RP, De Bari B, Ben-Haim S, Blay JY, Brink A, Estrada-Lobato E, Fanti S, Golubic AT, Hatazawa J, Israel O, Kiess A, Knoll P, Kunikowska J, Louw L, Mariani G, Mirzaei S, Orellana P, Prior JO, Urbain JL, Vichare S, Vinjamuri S, Virgolini I, Scott AM. Pascual TNB, et al. Eur J Nucl Med Mol Imaging. 2024 Jul;51(8):2320-2331. doi: 10.1007/s00259-024-06657-2. Epub 2024 Mar 8. Eur J Nucl Med Mol Imaging. 2024. PMID: 38453729 Free PMC article.
PSMA+ Extracellular Vesicles Are a Biomarker for SABR in Oligorecurrent Prostate Cancer: Analysis from the STOMP-like and ORIOLE Trial Cohorts.
Andrews JR, Kim Y, Horjeti E, Arafa A, Gunn H, De Bruycker A, Phillips R, Song D, Childs DS, Sartor OA, Orme JJ, Chaudhuri AA, Tran P, Kiess A, Sutera P, Mercier C, Ost P, Park SS, Lucien F. Andrews JR, et al. Clin Cancer Res. 2025 Mar 17;31(6):1142-1149. doi: 10.1158/1078-0432.CCR-24-3027. Clin Cancer Res. 2025. PMID: 39820657 Free PMC article. Clinical Trial.
Outcomes of Radium-223 and Stereotactic Ablative Radiotherapy Versus Stereotactic Ablative Radiotherapy for Oligometastatic Prostate Cancers: The RAVENS Phase II Randomized Trial.
Wang JH, Sherry AD, Bazyar S, Sutera P, Radwan N, Phillips RM, Deek MP, Lu J, Dipasquale S, Deville C, DeWeese TL, Song DY, Wang H, Hobbs RF, Malek R, Dudley SA, Greco SC, Antonarakis ES, Marshall CH, Denmeade S, Paller CJ, Carducci MA, Pienta KJ, Oz OK, Ramotar M, Leenstra JL, Park SS, Abramowitz MC, Desai N, Berlin A, Stish BJ, Tang C, Tran PT, Kiess AP. Wang JH, et al. Among authors: kiess ap. J Clin Oncol. 2025 Jun 20;43(18):2059-2068. doi: 10.1200/JCO-25-00131. Epub 2025 May 7. J Clin Oncol. 2025. PMID: 40334149 Free PMC article. Clinical Trial.
Machine learning predicts conventional imaging metastasis-free survival (MFS) for oligometastatic castration-sensitive prostate cancer (omCSPC) using prostate-specific membrane antigen (PSMA) PET radiomics.
Cao Y, Sutera P, Silva Mendes W, Yousefi B, Hrinivich T, Deek M, Phillips R, Song D, Kiess A, Cem Guler O, Torun N, Reyhan M, Sawant A, Marchionni L, Simone NL, Tran P, Onal C, Ren L. Cao Y, et al. Radiother Oncol. 2024 Oct;199:110443. doi: 10.1016/j.radonc.2024.110443. Epub 2024 Jul 31. Radiother Oncol. 2024. PMID: 39094629
Prostate-Specific Membrane Antigen PET Response Associates with Metastasis-Free Survival After Stereotactic Ablative Radiation in Oligometastatic Prostate Cancer.
Sutera P, Deek MP, Deek RA, Guler OC, Hurmuz P, Reyhan M, Rowe S, Radwan N, Dipasquale S, Hrinivich WT, Lowe K, Ren L, Saraiya B, Ennis R, Hathout L, Mayer T, Deweese TL, Song DY, Kiess A, Oymak E, Pienta K, Feng F, Pomper M, Ozyigit G, Tran PT, Onal C, Phillips RM. Sutera P, et al. Adv Radiat Oncol. 2024 Apr 13;9(7):101507. doi: 10.1016/j.adro.2024.101507. eCollection 2024 Jul. Adv Radiat Oncol. 2024. PMID: 38799104 Free PMC article.
Genomic Determinants Associated with Modes of Progression and Patterns of Failure in Metachronous Oligometastatic Castration-sensitive Prostate Cancer.
Sutera P, Song Y, Shetty AC, English K, Van der Eecken K, Guler OC, Wang J, Cao Y, Bazyar S, Verbeke S, Van Dorpe J, Fonteyne V, De Laere B, Mishra M, Rana Z, Molitoris J, Ferris M, Kiess A, Song DY, DeWeese T, Pienta KJ, Barbieri C, Marchionni L, Ren L, Sawant A, Simone N, Berlin A, Onal C, Tran PT, Ost P, Deek MP. Sutera P, et al. Eur Urol Oncol. 2025 Feb;8(1):111-118. doi: 10.1016/j.euo.2024.05.011. Epub 2024 Jun 10. Eur Urol Oncol. 2025. PMID: 38862340 Free article.
Validation of an artificial intelligence-based prognostic biomarker in patients with oligometastatic Castration-Sensitive prostate cancer.
Wang JH, Deek MP, Mendes AA, Song Y, Shetty A, Bazyar S, Van der Eecken K, Chen E, Showalter TN, Royce TJ, Todorovic T, Huang HC, Houck SA, Yamashita R, Kiess AP, Song DY, Lotan T, DeWeese T, Marchionni L, Ren L, Sawant A, Simone N, Berlin A, Onal C, Esteva A, Feng FY, Tran PT, Sutera P, Ost P. Wang JH, et al. Among authors: kiess ap. Radiother Oncol. 2025 Jan;202:110618. doi: 10.1016/j.radonc.2024.110618. Epub 2024 Nov 6. Radiother Oncol. 2025. PMID: 39510141 Free article.
90 results